Sarepta Therapeutics (SRPT) investor relations material

Key business highlights and financial performance

• Entered 2026 with $954 million in cash and equivalents, exceeding expectations for Q4 and full-year 2025 revenues at $1.86 billion.

• Elevidys generated $899 million in 2025, growing 9% year-over-year, while PMOs contributed $966 million.

• Maintains a $500 million annual revenue floor for Elevidys, with intentions to significantly exceed it.

• Restructured convertible debt, eliminating significant debt overhang for the decade, and expects to remain cash flow positive.

• Untapped $600 million revolver provides additional strategic flexibility.

Strategic vision and market opportunity

• Approximately 80% of the addressable ambulatory Duchenne muscular dystrophy population remains untreated with Elevidys, presenting significant growth potential.

• PMO therapies support a strong revenue trajectory and have an established safety profile with over 1,800 patients treated worldwide.

• Four approved therapies present significant untapped market opportunity.

Product and clinical development updates

• Elevidys demonstrated robust efficacy, slowing disease progression by 76% to over 100% in key endpoints, with long-term data showing sustained benefit.

• Over 1,100 patients have been treated with Elevidys globally, with safety evaluated in more than 200 clinical trial participants.

• Enhanced sales force and promotional campaigns planned for 2026 to communicate Elevidys' efficacy and safety.

• Endeavor Cohort 8 trial for non-ambulatory patients is ongoing, with results expected at the end of 2026.

• PMOs (Exondys 51, Vyondys 53, Amondys 45) have over a decade of stellar safety and real-world evidence supporting slowed disease progression and improved outcomes.